Idorsia Ltd announces positive results in the second phase III study of daridorexant in patients with insomnia.
Idorsia Ltd announced positive top-line results of the second pivotal Phase III study investigating 10 and 25 mg doses of its dual orexin receptor antagonist, daridorexant , in… read more.